Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion, significantly below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit was filed by Bleichmar Fonti & Auld LLP and is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a 180-day cliff method for reserving accounts [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

BENSALEM, Pa., Jan. 27, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Smart Digital Group Limited ("SDM" or the "Company") (NASDAQ: SDM). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SMART DIGITAL GROUP LIMITED (SDM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MARCH 16, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the ...

Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sale of Penumbra, Inc. to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock [1] - RAPT Therapeutics, Inc. is being investigated for its sale to GSK plc for $58.00 per share [2] - The firm may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders, operating on a contingent fee basis [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC free of charge to discuss their legal rights and options [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Group 1 - A class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. regarding potential securities fraud or unlawful business practices by the company and its officers [1][2] - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2] - The lawsuit alleges that certain financial institutions engaged in manipulative trading practices, including spoofed sell orders, to create a false impression of Quantum's stock price decline [4] Group 2 - The defendants in the lawsuit include CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada, among others, who are accused of deceiving investors into selling shares at artificially low prices [4] - Pomerantz LLP, the law firm handling the case, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [5]

Core Viewpoint - A class action lawsuit has been filed against Smart Digital Group Limited, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Smart Digital and certain officers and/or directors engaged in securities fraud [2]. - Investors have until March 16, 2026, to request to be appointed as Lead Plaintiff if they purchased Smart Digital securities during the Class Period [2]. Group 2: Stock Price and SEC Actions - On September 26, 2025, Smart Digital's stock price dropped 86.4% to close at $1.85 per share after a trading halt due to volatility [4]. - The SEC suspended trading in Smart Digital securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [4]. - Following the SEC suspension, NASDAQ also suspended trading in Smart Digital securities pending further information [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [5].

Core Viewpoint - A class action lawsuit has been filed against F5, Inc. concerning allegations of securities fraud and unlawful business practices related to a significant security breach and its impact on the company's financial performance [2][4]. Group 1: Lawsuit Details - The class action lawsuit involves F5 and certain officers and/or directors, with investors encouraged to contact Pomerantz LLP for participation [1][2]. - Investors who purchased F5 securities during the Class Period have until February 17, 2026, to request appointment as Lead Plaintiff [2]. Group 2: Security Breach Impact - On October 15, 2025, F5 disclosed a "long-term, persistent" breach affecting its BIG-IP product development and engineering management platforms, including the source code [4]. - Following the breach announcement, F5's stock price dropped by $47.82, or 13.93%, closing at $295.35 on October 16, 2025 [4]. - On October 27, 2025, F5 reported fiscal year 2025 results that significantly missed market growth expectations for fiscal year 2026, attributing this to the security breach [5]. - The subsequent announcement led to a further decline in F5's stock price by $30.76, or 10.31%, closing at $258.76 on October 28, 2025 [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Inovio Pharmaceuticals and its executives [1] Group 1: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3] - Inovio announced it will not pursue approval under the standard review timeline and plans to meet with the FDA to discuss options for accelerated approval [3] Group 2: Market Reaction - Following the FDA announcement, Inovio's stock price dropped by $0.56 per share, a decline of 24.45%, closing at $1.73 per share on December 29, 2025 [4]

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 27, 2025, to November 11, 2025, seeking damages for affected investors [1]. Company Overview - Beyond Meat operates in the food industry, focusing on the development, manufacturing, marketing, and sale of plant-based meat products under the "Beyond" brand in the U.S. and internationally [4]. Financial Performance and Challenges - Since early 2025, Beyond Meat has faced shrinking demand, increasing debt, and losses, with a primary goal of achieving positive EBITDA by the end of 2026 [5]. - Throughout the Class Period, the company emphasized operational efficiency and cost reduction while deemphasizing revenue growth [6]. Allegations of Misleading Statements - The complaint alleges that Defendants made materially false and misleading statements regarding the company's business and operations, including failing to disclose the likelihood of significant asset impairment charges [8]. - It is claimed that the book value of certain long-lived assets exceeded their fair value, which could impair the company's ability to file periodic reports with the SEC [8]. Stock Price Impact - The truth began to emerge on October 24, 2025, when Beyond Meat reported expectations of a non-cash impairment charge, leading to a stock price drop of 23.06% to $2.185 per share [9]. - Subsequent announcements regarding delays in financial reporting and actual impairment charges resulted in further declines in stock price, with a notable drop of 8.96% to $1.22 per share on November 11, 2025 [11][12].

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Klarna Group plc (“Klarna” or the “Company”) (NYSE: KLAR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Klarna Group Class Action Lawsuit? Do you, or did you, own shares of Klarna Group plc (NYSE: KLAR)?Did you purchase your shares pursuant or traceable to, the Company’s September 2025 IPO?Did you ...